Veradermics, Incorporated (MANE) is a late clinical-stage biopharmaceutical company developing novel treatments for dermatologic and aesthetic conditions, led by oral, non-hormonal hair-loss candidate VDPHL01. As a development-stage drugmaker with no product revenue, its valuation and analyst targets hinge heavily on clinical catalysts rather than current earnings.
Five recent, attributed targets form the basis of the $170 central figure: Citi analyst Geoff Meacham at $160 (maintained in September and October 2026), Jefferies at $182 (September 2026), Needham at $164 (August 2026), LifeSci Capital at $170 (August 2026), and B. Riley Securities at $170 (initiated July 2026). Their arithmetic mean is $169.20, rounded to $170. For context, S&P Global's broader seven-analyst aggregate carries an average price target near $163.50 and a Strong Buy consensus rating, with estimates spanning roughly $135 to $182.
The spread between $160 and $182 reflects genuine disagreement about how much credit to give VDPHL01 ahead of data. Bullish analysts emphasize the favorable risk-reward into the Study 304 readout and the company's long cash runway, while more conservative targets discount for execution and clinical risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
MANE last traded around $136.66, near the top of a 52-week range of $32.00 to $139.12, following a powerful advance from its February 2026 IPO price of $17. Reaching $170 would require a gain of about 24% from current levels, which is substantial for any equity and especially demanding for a pre-commercial biotech that has already repriced sharply upward.
The most likely path toward that level runs through the Phase 3 topline data for VDPHL01 in male pattern hair loss, expected in the November-to-December 2026 window. Because the company reports no meaningful revenue and widening net losses, the near-term share price is driven by sentiment, trial outcomes, and analyst revisions rather than conventional earnings growth.
MANE has been in a strong uptrend since its IPO, but the steepness of that move leaves limited established support. The 52-week high near $139 acts as the immediate resistance zone that bulls would need to clear before a push toward $170. Below the current price, reference support areas include the prior consolidation band near $108–$110 and a lower zone near $98, both visible during the stock's 2026 pullbacks. A decisive break above the $139 area, sustained on volume, would be the clearest technical confirmation of an extended advance.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may differ and the true driver here is event-driven rather than calendar-driven. The critical item to monitor is the Phase 3 Study 304 data for VDPHL01, expected in November or December 2026. Investors should also watch the next quarterly earnings report, estimated around November 12, 2026, along with analyst target revisions, any update to the cash runway, and FDA (Food and Drug Administration) or clinical timeline commentary.
For traders who prefer a data-driven, real-time view of shifting momentum, Tickeron's AI Daily Buy/Sell Signals offer a practical complement to fundamental research. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. I find these signals helpful for spotting changes in momentum around event-driven names like this one. Traders can use these signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening alone.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MANE broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 8 similar instances where the stock broke above the upper band. In 8 of the 8 cases the stock fell afterwards. This puts the odds of success at 90%.
The 10-day RSI Indicator for MANE moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 10 similar instances where the indicator moved out of overbought territory. In 8 of the 10 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MANE as a result. In 13 of 16 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for MANE turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In 7 of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
MANE moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MANE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where MANE advanced for three days, in 42 of 47 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 43 of 45 cases where MANE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.127) is normal, around the industry mean (3.596). P/E Ratio (-55.597) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. MANE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MANE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology